Low-density lipoprotein-independent effects of statins
- 1 December 1999
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 10 (6) , 543-560
- https://doi.org/10.1097/00041433-199912000-00010
Abstract
Statins have pleiotropic properties that complement their cholesterol-lowering effects. These properties may partly account for their established benefit in the prevention of coronary artery disease beyond the reduction of LDL-cholesterol levels. The most widely recognized properties are reviewed here. They include: (i) nitric oxide-mediated improvement of endothelial dysfunction and upregulation of endothelin-1 expression; (ii) antioxidant effects; (iii) anti-inflammatory properties; (iv) inhibition of cell proliferation with anticarcinogenic actions in animals; (v) stabilization of atherosclerotic plaques; (vi) anticoagulant effects; and (vii) inhibition of graft rejection after heart and kidney transplantation. As advances are made in our knowledge, new properties are steadily being uncovered. Pleiotropic effects are currently being given consideration when instituting combination therapy for patients at high cardiovascular risk. Some pleiotropic effects are negative, and may account for occasional untoward drug interactions. For many of these new properties, the clinical relevance has not been established. The challenge for the future will be to design and carry out appropriate clinical trials to establish their relative importance in the prevention of coronary artery disease.Keywords
This publication has 127 references indexed in Scilit:
- Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)The American Journal of Cardiology, 1999
- CorrespondenceAtherosclerosis, 1999
- Inhibition of proinflammatory cytokine production by pravastatinThe Lancet, 1999
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998
- Statins and fibrinogenThe Lancet, 1998
- AtorvastatinDrugs, 1997
- Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophagesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- The effect of Simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscleThe American Journal of Cardiology, 1996
- Effect of Cholesterol Lowering on Intravascular Pools of TFPI and Its Anticoagulant Potential in Type II HyperlipoproteinemiaArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophagesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993